The synergistic inhibitory effect of LAG3 and PD-1 on T cells has been confirmed in a variety of tumors, including NSCLC [158], melanoma [159], renal cell carcinoma (RCC) [160, 161], head and neck cancer [6], and breast cancer [162, 163]. Here, LAG3 is linked to renal cell carcinoma.